Abbonarsi

Pediatric cardiovascular safety: Challenges in drug and device development and clinical application - 15/10/12

Doi : 10.1016/j.ahj.2012.07.019 
Katherine E. Bates, MD a, , k , Victoria L. Vetter, MD, MPH a, k, Jennifer S. Li, MD, MHS b, k, Susan Cummins, MD, MPH c, k, Fernando Aguel, MS c, k, Christopher Almond, MD, MPH d, k, Anne M. Dubin, MD e, k, Josephine Elia, MD a, k, John Finkle, MD f, k, Elizabeth A. Hausner, DVM c, k, Francesca Joseph, MD c, k, Abraham M. Karkowsky, MD, PhD c, k, Matthew Killeen, MD, PhD g, k, Jodi Lemacks, JD h, k, Lisa Mathis, MD c, k, Ann W. McMahon, MD c, k, Ellen Pinnow, MS c, k, Ignacio Rodriguez, MD i, k, Norman L. Stockbridge, MD, PhD c, k, Margaret Stockwell, MD j, k, Melissa Tassinari, PhD c, k, Mitchell W. Krucoff, MD b, k
a Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 
b Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 
c US Food and Drug Administration, Silver Spring, MD 
d Children's Hospital Boston, Boston MA 
e Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA 
f GlaxoSmithKline, Upper Providence, PA 
g Pharmaceutical Consultant 
h Mended Little Hearts, Dallas, TX 
i Hoffman-LaRoche, Nutley, NJ 
j Health Canada, Ottawa, Ontario, Canada 

Reprint requests: Katherine E. Bates, MD, Children's Hospital of Philadelphia, Division of Cardiology, 3401 Civic Center Blvd., Philadelphia, PA 19104.

Riassunto

Development of pediatric medications and devices is complicated by differences in pediatric physiology and pathophysiology (both compared with adults and within the pediatric age range), small patient populations, and practical and ethical challenges to designing clinical trials. This article summarizes the discussions that occurred at a Cardiac Safety Research Consortium–sponsored Think Tank convened on December 10, 2010, where members from academia, industry, and regulatory agencies discussed important issues regarding pediatric cardiovascular safety of medications and cardiovascular devices. Pediatric drug and device development may use adult data but often requires additional preclinical and clinical testing to characterize effects on cardiac function and development. Challenges in preclinical trials include identifying appropriate animal models, clinically relevant efficacy end points, and methods to monitor cardiovascular safety. Pediatric clinical trials have different ethical concerns from adult trials, including consideration of the subjects' families. Clinical trial design in pediatrics should assess risks and benefits as well as incorporate input from families. Postmarketing surveillance, mandated by federal law, plays an important role in both drug and device safety assessment and becomes crucial in the pediatric population because of the limitations of premarketing pediatric studies. Solutions for this wide array of issues will require collaboration between academia, industry, and government as well as creativity in pediatric study design. Formation of various epidemiologic tools including registries to describe outcomes of pediatric cardiac disease and its treatment as well as cardiac effects of noncardiovascular medications, should inform preclinical and clinical development and improve benefit-risk assessments for the patients. The discussions in this article summarize areas of emerging consensus and other areas in which consensus remains elusive and provide suggestions for additional research to further our knowledge and understanding of this topic.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Proceedings from the First Pediatric Cardiac Safety Research Consortium Think Tank is an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, Children's Hospital of Philadelphia, Health Canada, and the US Food and Drug Administration.


© 2012  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 164 - N° 4

P. 481-492 - Ottobre 2012 Ritorno al numero
Articolo precedente Articolo precedente
  • Study design for the “effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion” (METOCARD-CNIC): A randomized, controlled parallel-group, observer-blinded clinical trial of early pre-reperfusion metoprolol administration in ST-segment elevation myocardial infarction
  • Borja Ibanez, Valentin Fuster, Carlos Macaya, Vicente Sánchez-Brunete, Gonzalo Pizarro, Pedro López-Romero, Alonso Mateos, Jesús Jiménez-Borreguero, Antonio Fernández-Ortiz, Ginés Sanz, Leticia Fernández-Friera, Ervigio Corral, Maria-Victoria Barreiro, Borja Ruiz-Mateos, Javier Goicolea, Rosana Hernández-Antolín, Carlos Acebal, Juan Carlos García-Rubira, Agustín Albarrán, José Luis Zamorano, Isabel Casado, Juan Valenciano, Felipe Fernández-Vázquez, José María de la Torre, Armando Pérez de Prado, José Antonio Iglesias-Vázquez, Pedro Martínez-Tenorio, Andrés Iñiguez
| Articolo seguente Articolo seguente
  • Regionalization of post–cardiac arrest care: Implementation of a cardiac resuscitation center
  • Alan C. Heffner, David A. Pearson, Marcy L. Nussbaum, Alan E. Jones

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.